GlassScriptPhysician profile
Kash K Biddle
NPI 1073566659
$5,018.75
in general payments reported to CMS, 2019-2025
37 companies · $80.43 in 2025
The $80.43 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $902 · 2021: $1,373 · 2022: $750 · 2023: $595 · 2024: $402 · 2025: $80.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.10 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $459.77 | 2019-2023 | |
| Astellas Pharma US INC | $383.72 | 2019-2024 | Veozah |
| Allergan, INC. | $299.00 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.96 | 2020-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $251.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.84 | 2019-2021 | |
| Lilly USA, LLC | $196.97 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $174.92 | 2020-2025 | Otezla, Repatha |
| Horizon Therapeutics Plc | $172.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $165.50 | 2020-2024 | Airsupra |
| Abbott Laboratories | $139.02 | 2021-2025 | Freestyle Libre 3 |
| Corium, LLC | $129.67 | 2022-2024 | Azstarys, Azstarys |
| Otsuka America Pharmaceutical, INC. | $127.02 | 2021-2024 | Rexulti |
| Glaxosmithkline, LLC. | $121.74 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $118.51 | 2021 | |
| Supernus Pharmaceuticals, INC. | $98.46 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $94.98 | 2019-2020 | |
| Almatica Pharma LLC | $51.17 | 2023-2024 | Loreev Xr, Gralise |
| Scilex Pharmaceuticals INC. | $41.69 | 2019 | |
| Ironshore Pharmaceuticals INC. | $41.29 | 2019-2023 | Jornay Pm |
| Eisai INC. | $33.57 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.32 | 2022 | |
| Dexcom, INC. | $24.56 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $23.69 | 2021 | |
| Exact Sciences Corporation | $20.67 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.85 | 2022 | |
| Boston Scientific Corporation | $18.76 | 2020 | |
| Kaleo, INC. | $18.58 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.76 | 2025 | Fanapt |
| Celgene Corporation | $15.39 | 2019 | |
| Amarin Pharma, INC. | $15.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.14 | 2021 | |
| Sanofi Pasteur INC. | $13.85 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.57 | 2021 | |
| Genentech USA, INC. | $12.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kash Biddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.